The impact of glycemic traits on prostate cancer risk in Prostate Cancer Association Group to Investigate Cancer-Associated Alterations in the Genome consortium using Mendelian randomization
| All SNPs | Inverse variance weighting with multiplicative random effects | MR-Egger | Weighted median | ||||||
| OR | 95% CI | I2 | OR | 95% CI | Intercept | Intercept p value | OR | 95% CI | |
| Glucose (mmol/L) (n=11) | 0.93 | 0.73 to 1.17 | 0.464 | 0.73 | 0.41 to 1.29 | 0.008 | 0.38 | 0.88 | 0.70 to 1.12 |
| HbA1c (%) (n=19) | 0.90 | 0.58 to 1.40 | 0.575 | 1.26 | 0.32 to 4.92 | −0.005 | 0.62 | 1.03 | 0.65 to 1.63 |
| Type 2 diabetes (n=112) | 1.02 | 0.97 to 1.07 | 0.690 | 0.98 | 0.86 to 1.10 | 0.003 | 0.50 | 0.97 | 0.93 to 1.02 |
| Excluding pleiotropic SNPs* | |||||||||
| Glucose (mmol/L) (n=10) | 1.01 | 0.81 to 1.24 | 0.263 | 0.75 | 0.48 to 1.19 | 0.01 | 0.20 | 0.90 | 0.72 to 1.13 |
| Type 2 diabetes (n=111) | 1.02 | 0.97 to 1.07 | 0.686 | 0.98 | 0.87 to 1.11 | 0.003 | 0.48 | 0.98 | 0.93 to 1.03 |
*No pleiotropic SNPs identified for HbA1c.
SNP, single-nucleotide polymorphism.